Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.

Burtness B, Bauman JE, Galloway T.

Lancet Oncol. 2013 Jul;14(8):e302-9. doi: 10.1016/S1470-2045(13)70085-8. Review.

PMID:
23816296
[PubMed - indexed for MEDLINE]
2.

Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.

Box C, Zimmermann M, Eccles S.

Front Biosci (Landmark Ed). 2013 Jan 1;18:520-42.

PMID:
23276940
[PubMed - indexed for MEDLINE]
3.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID:
16818711
[PubMed - indexed for MEDLINE]
Free Article
4.

Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, Lardon F.

Oncologist. 2013;18(7):850-64. doi: 10.1634/theoncologist.2013-0013. Epub 2013 Jul 2. Review.

PMID:
23821327
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.

Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, Bier H, Keller U.

Oncotarget. 2011 Aug;2(8):599-609.

PMID:
21865609
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
[PubMed - indexed for MEDLINE]
7.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
[PubMed - indexed for MEDLINE]
8.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
9.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID:
16736979
[PubMed - indexed for MEDLINE]
10.

Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.

Bozec A, Peyrade F, Milano G.

Anticancer Agents Med Chem. 2013 Mar;13(3):389-402. Review.

PMID:
23092267
[PubMed - indexed for MEDLINE]
11.

Epidermal growth factor receptor biology in head and neck cancer.

Kalyankrishna S, Grandis JR.

J Clin Oncol. 2006 Jun 10;24(17):2666-72. Review.

PMID:
16763281
[PubMed - indexed for MEDLINE]
12.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, BarĂ³n AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

PMID:
15701870
[PubMed - indexed for MEDLINE]
Free Article
13.

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Goffin JR, Zbuk K.

Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007. Review.

PMID:
24054705
[PubMed - indexed for MEDLINE]
14.

Promising new molecular targeted therapies in head and neck cancer.

Dorsey K, Agulnik M.

Drugs. 2013 Mar;73(4):315-25. doi: 10.1007/s40265-013-0025-3. Review.

PMID:
23440867
[PubMed - indexed for MEDLINE]
15.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
[PubMed - indexed for MEDLINE]
16.

Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

Cooper JB, Cohen EE.

Head Neck. 2009 Aug;31(8):1086-94. doi: 10.1002/hed.21109. Review.

PMID:
19378324
[PubMed - indexed for MEDLINE]
17.

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C.

Cancer Res. 2010 May 1;70(9):3647-56. doi: 10.1158/0008-5472.CAN-09-3360. Epub 2010 Apr 13.

PMID:
20388807
[PubMed - indexed for MEDLINE]
Free Article
18.

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.

Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, Schlegel J.

Int J Mol Med. 2010 Nov;26(5):713-21.

PMID:
20878094
[PubMed - indexed for MEDLINE]
19.

The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.

Koukourakis G, Kouloulias V, Koukourakis M, Kouvaris J, Zacharias G, Gouliamos A.

J BUON. 2009 Jan-Mar;14(1):19-25. Review.

PMID:
19373942
[PubMed - indexed for MEDLINE]
20.

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA.

Drug Resist Updat. 2011 Dec;14(6):260-79. doi: 10.1016/j.drup.2011.08.002. Epub 2011 Sep 14. Review.

PMID:
21920801
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk